Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Antoine Leuzy; Stephen F Carter; Konstantinos Chiotis; Ove Almkvist; Anders Wall; Agneta Nordberg

doi:10.3233/JAD-142952

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Antoine Leuzy, Stephen F Carter, Konstantinos Chiotis, Ove Almkvist, Anders Wall, Agneta Nordberg

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [11C]Pittsburgh compound-B ([11C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [11C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [11C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [11C]PIB PET and CSF sampling. Cutoffs of >1.41 ([11C]PIB),

Original language	English
Journal	Journal of Alzheimer's disease : JAD
Volume	45
Issue number	4
DOIs	https://doi.org/10.3233/JAD-142952
Publication status	Published - 1 Jan 2015

Keywords

Alzheimer's disease
[${11}^C$]PIB
amyloid
cerebrospinal fluid
mild cognitive impairment
positron emission tomography
tau

Access to Document

10.3233/JAD-142952

Cite this

@article{d3b6c79ec7754360910997db73bde35a,

title = "Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.",

abstract = "BACKGROUND: Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [11C]Pittsburgh compound-B ([11C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [11C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [11C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [11C]PIB PET and CSF sampling. Cutoffs of >1.41 ([11C]PIB),",

keywords = "Alzheimer's disease, [${11}^C$]PIB, amyloid, cerebrospinal fluid, mild cognitive impairment, positron emission tomography, tau",

author = "Antoine Leuzy and Carter, {Stephen F} and Konstantinos Chiotis and Ove Almkvist and Anders Wall and Agneta Nordberg",

year = "2015",

month = jan,

day = "1",

doi = "10.3233/JAD-142952",

language = "English",

volume = "45",

journal = "Journal of Alzheimer's disease : JAD",

issn = "1875-8908",

publisher = "IOS Press",

number = "4",

}

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. / Leuzy, Antoine; Carter, Stephen F; Chiotis, Konstantinos et al.
In: Journal of Alzheimer's disease : JAD, Vol. 45, No. 4, 01.01.2015.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

AU - Leuzy, Antoine

AU - Carter, Stephen F

AU - Chiotis, Konstantinos

AU - Almkvist, Ove

AU - Wall, Anders

AU - Nordberg, Agneta

PY - 2015/1/1

Y1 - 2015/1/1

N2 - BACKGROUND: Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [11C]Pittsburgh compound-B ([11C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [11C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [11C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [11C]PIB PET and CSF sampling. Cutoffs of >1.41 ([11C]PIB),

AB - BACKGROUND: Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [11C]Pittsburgh compound-B ([11C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [11C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [11C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [11C]PIB PET and CSF sampling. Cutoffs of >1.41 ([11C]PIB),

KW - Alzheimer's disease

KW - [${11}^C$]PIB

KW - amyloid

KW - cerebrospinal fluid

KW - mild cognitive impairment

KW - positron emission tomography

KW - tau

U2 - 10.3233/JAD-142952

DO - 10.3233/JAD-142952

M3 - Article

C2 - 25649653

SN - 1875-8908

VL - 45

JO - Journal of Alzheimer's disease : JAD

JF - Journal of Alzheimer's disease : JAD

IS - 4

ER -

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Abstract

Keywords

Access to Document

Fingerprint

Cite this